Articles about Eikon Therapeutics.
In The News | Feb 15, 2023
Ranked: The biggest healthcare VC deals of 2022
Drug discovery and development firm Eikon Therapeutics aims to better understand biochemical regulation using proprietary platforms that can examine protein interactions in living cells.
In The News | Jan 05, 2022
Top Life Sciences Startups to Watch in 2022
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
In The News | Dec 20, 2021
34 healthcare and biotech startups that are set to take off in 2022, according to top investors
Eikon is now being led by one of the drug industry's most accomplished R&D leaders: Roger Perlmutter, who left the drug-making giant Merck to become CEO of Eikon in May 2021.
In The News | Nov 21, 2021
C&EN’s 2021 10 Start-Ups to Watch
Superresolution fluorescence microscopy shines a light on protein movement in living cells to aid drug discovery
In The News | Sep 22, 2021
The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.
In The News | May 05, 2021
Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets
Roger Perlmutter, M.D., Ph.D., has taken up the CEO post at Eikon Therapeutics. The startup disclosed the hiring of the former president of Merck Research Laboratories alongside news that it has raised a $148 million series A round to apply live-cell super-resolution microscopy to drug discovery.
